诺和诺德减重药广告被指误导消费者，FDA发出警告

Core Viewpoint - The FDA issued a warning letter to Novo Nordisk regarding misleading advertisements for its oral weight loss drug semaglutide, amid increasing competition in the weight loss drug market [1][2]. Group 1: FDA Warning - The FDA's warning letter claims that Novo Nordisk's advertisements misleadingly suggest that semaglutide is more effective than other GLP-1 weight loss drugs, violating the Federal Food, Drug, and Cosmetic Act [2]. - The FDA requires Novo Nordisk to take immediate action to address the misleading information in its advertisements, including halting all ads that contain such information [2]. Group 2: Market Context - As millions of Americans begin using GLP-1 weight loss drugs, companies are investing heavily in direct-to-consumer marketing, with approximately 12% of the U.S. population currently using these medications [1]. - Semaglutide became the first FDA-approved oral GLP-1 weight loss drug at the end of last year, ahead of competitors like Eli Lilly, and was officially launched in the U.S. earlier this year [1]. Group 3: Competitive Landscape - Novo Nordisk faces additional challenges, including competition from Hims, which has launched a generic version of semaglutide at a price as low as $49, leading to a significant drop in Novo Nordisk's stock price [3]. - Eli Lilly's oral weight loss drug is expected to receive approval for market entry in April of this year, intensifying competition in the sector [4].